News

The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.

When sessions, late-breaking research, and more concludes, there is no shortage of things to do in the nation’s capital.

The 5th annual RAD conference kicks off April 29, 2023, in Washington, DC.

ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.

Some patients with the condition may experience exacerbation or new onset.

Let us know what content you want to see from RAD.

Using mass spectrometry, researchers examined novel changes to gather updated metastasis information.

Results of a new study indicate that baricitinib offers a potential therapeutic option with a favorable benefit-risk profile for pediatric patients with moderate-to-severe AD.

Inhibitor etanercept alleviated pathological changes and inflammation in induced psoriasis.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are popular for the month of April.

The results of a new study reveal that the the antibody works by activating the immune response to fight cancer and slows melanoma growth in mice.

Physical activity and exercise may lead to improved mental health but exacerbate skin conditions.

Galderma announced the approval of a injectable poly-L-lactic acid to correct fine lines and wrinkles.

Patients more commonly reported skin aging manifestations when they experienced higher levels of stress.

In this week’s Pointers with Portela, the 208SkinDoc explains why vitamin C serums can occasionally have an unpleasant smell.

Learn more about the in-depth topics covered in the April 2023 issue of Dermatology Times®.

ASLAN Pharmaceuticals will present 2 late-breaking abstracts and 2 additional abstracts.

Learning from mentors and developing a solid foundation in dermatology are just a few of the necessary steps to boost your career as a dermatology APP.

Such factors may include transepidermal water loss and skin barrier function.

With dermoscopy and skin thickness assessments, researchers said it may be possible to detect cutaneous-involved acromelagy.

At least 1 legal case suggests that providers have a duty to minimize risks during the transition period to a new electronic health record system.

The risk remained significantly increased for both sexes as well ,whether or not the patient had depression, substance use disorder, or alcohol use disorder.

Researchers said the treatment may improve post-acne erythema.

When compared to a vehicle control cream, researchers said delgocitinib cream proved more efficacious.

This week's edition of the Mainstream Patient features stories about addictive behaviors stemming from skin care culture, the 21 best hyaluronic acid serums, and the struggles behind finding the right vitiligo treatment.

Although our tax code changes somewhat regularly, both real estate and cash value life insurance have shown superior tax treatment for decades.

From explaining how medications work and should be taken to reviewing potential adverse effects and financial details, pharmacists are crucial resources for patients undergoing treatment for skin cancer.

ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.

Results of the phase 3 ECZTRA 6 trial found that the efficacy of the drug was maintained by more than 50% of patients at 52 weeks.

Ruxolitinib is the first and only approved treatment for repigmentation in the European Union.